Primary Sclerosing Cholangitis, Inflammatory Bowel Disease, and Colon Cancer

 

 Buy Article Permissions and Reprints

ABSTRACT

The prevalence of inflammatory bowel disease (IBD) in patients with PSC differs in various part of the world. Ulcerative colitis (UC) is most common, but 1 to 14% of all primary sclerosing cholangitis (PSC) patients have Crohn disease with colonic involvement. Many PSC patients without clinical symptoms of IBD have colonoscopic and histological findings compatible with IBD, and the subclinical phase may last several years before onset of symptoms of active colitis. The characteristics of UC in patients with PSC are different from those in UC patients without PSC. The colitis is usually substantial, the clinical course of the colitis is quiescent, and rectal sparing is common. Moreover, PSC patients with UC have a higher risk of developing colorectal dysplasia/carcinoma than UC patients without PSC. In patients having an ileal pelvic pouch with ileal anal anastomosis, PSC is a risk factor for development of pouchitis. It is important that all PSC patients with UC are included in colonoscopic surveillance programs.

REFERENCES

• 1 Smith M, Loe S. Sclerosing cholangitis: review of recent case reports and associated diseases and four new cases.  Am J Surg. 1965;  110 239-246
  CrossrefPubMedGoogle Scholar
• 2 Broomé U, Glaumann H, Hellers G et al.. Liver disease in ulcerative colitis: an epidemiological and follow up study in the county of Stockholm.  Gut. 1994;  35 84-89
  PubMedGoogle Scholar
• 3 Atkinson A J, Carroll W W. Sclerosing cholangitis, association with regional enteritis.  JAMA. 1964;  188 183-184
  PubMedGoogle Scholar
• 4 Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis.  Semin Liver Dis. 1991;  11 31-39
  Article in Thieme ConnectPubMedGoogle Scholar
• 5 Broomé U, Glaumann H, Hultcrantz R. Liver histology and follow up of 68 patients with ulcerative colitis and normal liver function tests.  Gut. 1990;  31 468-471
  PubMedGoogle Scholar
• 6 Wiesner R H, LaRusso N F. Clinicopathologic features of the syndrome of primary sclerosing cholangitis.  Gastroenterology. 1980;  79 200-206
  PubMedGoogle Scholar
• 7 Aadland E, Schrumpf E, Fausa O et al.. Primary sclerosing cholangitis: a long-term follow-up study.  Scand J Gastroenterol. 1987;  22 655-664
  PubMedGoogle Scholar
• 8 Chapman R WG, Arborgh B AM, Rhodes J M et al.. Primary sclerosing cholangitis: a review of its clinical features, cholangiography and hepatic histology.  Gut. 1980;  21 870-877
  PubMedGoogle Scholar
• 9 Riley T R, Schoen R E, Lee R G, Rakela J. A case series of transplant recipients who despite immunosuppression developed inflammatory bowel disease.  Am J Gastroenterol. 1997;  92 279-282
  PubMedGoogle Scholar
• 10 Broomé U, Olsson R, Lööf L et al.. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis.  Gut. 1996;  38 610-615
  PubMedGoogle Scholar
• 11 Farrant J M, Hayllar K M, Wilkinson M L et al.. Natural history and prognostic variables in primary sclerosing cholangitis.  Gastroenterology. 1991;  100 1710-1717
  PubMedGoogle Scholar
• 12 Wiesner R, Grambsch P, Dickson R et al.. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis.  Hepatology. 1989;  10 430-436
  PubMedGoogle Scholar
• 13 Dickson E R, Murtaugh P A, Wiesner R H et al.. Primary sclerosing cholangitis: refinement and validation of survival models.  Gastroenterology. 1992;  103 1893-1899
  CrossrefPubMedGoogle Scholar
• 14 Shetty K, Rybicki L, Carey W D. The Child-Pugh classification as a prognostic indicator for survival in primary sclerosing cholangitis.  Hepatology. 1997;  25 1049-1053
  CrossrefPubMedGoogle Scholar
• 15 Boberg K M, Rocca G, Egeland T et al.. Time-dependent Cox regression model is superior in prediction of prognosis in primary sclerosing cholangitis.  Hepatology. 2002;  35 652-657
  CrossrefPubMedGoogle Scholar
• 16 Boberg K M, Bergquist A, Mitchell S et al.. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation.  Scand J Gastroenterol. 2002;  37 1205-1211
  CrossrefPubMedGoogle Scholar
• 17 Okada H, Mizuno M, Yamamoto K, Tsuji T. Primary sclerosing cholangitis in Japanese patients: association with inflammatory bowel disease.  Acta Med Okayama. 1996;  50 227-235
  PubMedGoogle Scholar
• 18 Takikawa H, Manabe T. Primary sclerosing cholangitis in Japan-analysis of 192 cases.  J Gastroenterol. 1997;  32 134-137
  CrossrefPubMedGoogle Scholar
• 19 Escorsell A, Pares A, Rodes J et al.. Epidemiology of primary sclerosing cholangitis in Spain.  J Hepatol. 1994;  21 787-791
  CrossrefPubMedGoogle Scholar
• 20 Kochhar R, Goenka M K, Das K et al.. Primary sclerosing cholangitis: an experience from India.  J Gastroenterol Hepatol. 1996;  11 429-433
  PubMedGoogle Scholar
• 21 Kingham J GC, Kochar N, Gravenor M B. Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom.  Gastroenterology. 2004;  126 1929-1930
  CrossrefPubMedGoogle Scholar
• 22 Bergquist A, Ekbom A, Olsson R et al.. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis.  J Hepatol. 2002;  36 321-327
  CrossrefPubMedGoogle Scholar
• 23 Lundqvist K, Broomé U. Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study.  Dis Colon Rectum. 1997;  40 451-456
  CrossrefPubMedGoogle Scholar
• 24 Olsson R, Danielsson A, Järnerot G et al.. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis.  Gastroenterology. 1991;  100 1319-1323
  CrossrefPubMedGoogle Scholar
• 25 Rasmussen H H, Fallingborg J F, Mortensen P B et al.. Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn’s disease.  Scand J Gastroenterol. 1997;  32 604-610
  CrossrefPubMedGoogle Scholar
• 26 McGarity B, Bansi D S, Robertsson D AF, Millward-Sadler G H, Shepherd H A. Primary sclerosing cholangitis: an important and prevalent complication of Crohn’s disease.  Eur J Gastroenterol Hepatol. 1991;  3 361-364
  PubMedGoogle Scholar
• 27 Faubion Jr W A, Loftus E V, Sandborn W J, Freese D K, Perrault J. Pediatric “PSC-IBD”: a descriptive report of associated inflammatory bowel disease among pediatric patients with PSC.  J Pediatr Gastroenterol Nutr. 2001;  33 296-300
  CrossrefPubMedGoogle Scholar
• 28 Loftus Jr E V, Harewood G C, Loftus C G et al.. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis.  Gut. 2005;  54 91-96
  CrossrefPubMedGoogle Scholar
• 29 Loftus E V, Sandborn W J, Lindor K D, LaRusso N F. Interactions between chronic liver disease and inflammatory bowel disease.  Inflamm Bowel Dis. 1997;  3 288-302
  CrossrefPubMedGoogle Scholar
• 30 Broomé U, Glaumann H, Hellers G et al.. Liver disease in ulcerative colitis. An epidemiological and follow-up study in the county of Stockholm.  Gut. 1994;  35 84-89
  PubMedGoogle Scholar
• 31 Outwater E, Kaplan M M, Bankoff M S. Lymphadenopathy in sclerosing cholangitis: pitfall in the diagnosis of malignant biliary obstruction.  Gastrointest Radiol. 1992;  17 157-160
  CrossrefPubMedGoogle Scholar
• 32 Hirche T O, Russler J, Braden B et al.. Sonographic detection of perihepatic lymphadenopathy is an indicator for primary sclerosing cholangitis in patients with inflammatory bowel disease.  Int J Colorectal Dis. 2004;  19 586-594
  CrossrefPubMedGoogle Scholar
• 33 Ludwig J, Barham S S, La Russo N F et al.. Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis.  Hepatology. 1981;  1 632-640
  PubMedGoogle Scholar
• 34 MacCarty R L, La Russo N F, May G R et al.. Cholangiocarcinoma complicating primary sclerosing cholangitis: cholangiographic appearances.  Radiology. 1985;  156 43-46
  PubMedGoogle Scholar
• 35 Rabinovitz M, Gavaler J S, Schade R R et al.. Does primary sclerosing cholangitis occurring in association with inflammatory bowel disease differ from that occurring in the absence of inflammatory bowel disease? A study of sixty-six subjects.  Hepatology. 1990;  11 7-11
  PubMedGoogle Scholar
• 36 Moayyeri A, Daryani N E, Bahrami H et al.. Clinical course of ulcerative colitis in patients with and without primary sclerosing cholangitis.  J Gastroenterol Hepatol. 2005;  20 366-370
  CrossrefPubMedGoogle Scholar
• 37 Broomé U, Löfberg R, Lundqvist K, Veress B. Subclinical time span of inflammatory bowel disease in patients with primary sclerosing cholangitis.  Dis Colon Rectum. 1995;  38 1301-1305
  CrossrefPubMedGoogle Scholar
• 38 Perdigoto R, Wiesner R H, La Russo N, Dozois R. Inflammatory bowel disease associated with primary sclerosing cholangitis: incidence, severity and relationship to liver disease.  Gastroenterology. 1991;  100 A238
  PubMedGoogle Scholar
• 39 Penna C, Dozois R, Tremaine W et al.. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis.  Gut. 1996;  38 234-239
  CrossrefPubMedGoogle Scholar
• 40 Zins B J, Sandborn W J, Penna C R et al.. Pouchitis disease course after orthotopic liver transplantation in patients with primary sclerosing cholangitis and an ileal pouch-anal anastomosis.  Am J Gastroenterol. 1995;  90 2177-2181
  PubMedGoogle Scholar
• 41 Tobias R, Wright J P, Kottler R E. Primary sclerosing cholangitis associated with inflammatory bowel disease in Cape Town, 1975-1981.  S Afr Med J. 1983;  63 229-235
  PubMedGoogle Scholar
• 42 Askling J, Dickman P W, Karlen P et al.. Family history as a risk factor for colorectal cancer in inflammatory bowel disease.  Gastroenterology. 2001;  120 1356-1362
  CrossrefPubMedGoogle Scholar
• 43 Rutter M, Saunders B, Wilkinson K et al.. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.  Gastroenterology. 2004;  126 451-459
  CrossrefPubMedGoogle Scholar
• 44 Broomé U, Lindberg G, Löfberg R. Primary sclerosing cholangitis in ulcerative colitis-a risk factor for the development of dysplasia and DNA aneuploidy?.  Gastroenterology. 1992;  102 1877-1880
  PubMedGoogle Scholar
• 45 Kornfeld D, Ekbom A, Ihre T. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study.  Gut. 1997;  41 522-525
  CrossrefPubMedGoogle Scholar
• 46 Brentnall T A, Haggitt R C, Rabinovitch P S et al.. Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis.  Gastroenterology. 1996;  110 331-338
  PubMedGoogle Scholar
• 47 D'Haens G R, Lashner B A, Hanauer S B. Pericholangitis and sclerosing cholangitis are risk factors for dysplasia and cancer in ulcerative colitis.  Am J Gastroenterol. 1993;  88 1174-1178
  PubMedGoogle Scholar
• 48 Leidenius M H, Farkkila M A, Karkkainen P et al.. Colorectal dysplasia and carcinoma in patients with ulcerative colitis and primary sclerosing cholangitis.  Scand J Gastroenterol. 1997;  32 706-711
  PubMedGoogle Scholar
• 49 Eaden J A, Abrams K, Mayberry J F. The risk of colorectal cancer in ulcerative colitis: a meta analysis.  Gut. 2001;  48 526-535
  CrossrefPubMedGoogle Scholar
• 50 Broomé U, Löfberg R, Veress B, Eriksson L S. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential.  Hepatology. 1995;  22 1404-1408
  CrossrefPubMedGoogle Scholar
• 51 Choi P M, Nugent F W, Rossi R L. Relationship between colorectal neoplasia and primary sclerosing cholangitis in ulcerative colitis.  Gastroenterology. 1992;  103 1707-1709
  PubMedGoogle Scholar
• 52 Gurbuz A K, Giardiello F M, Bayless T M. Colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.  Dis Colon Rectum. 1995;  38 37-41
  CrossrefPubMedGoogle Scholar
• 53 Loftus Jr E V, Sandborn W J, Tremaine W J et al.. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis.  Gastroenterology. 1996;  110 432-440
  CrossrefPubMedGoogle Scholar
• 54 Nuako K W, Ahlquist D A, Sandborn W J et al.. Primary sclerosing cholangitis and colorectal carcinoma in patients with chronic ulcerative colitis: a case-control study.  Cancer. 1998;  82 822-826
  CrossrefPubMedGoogle Scholar
• 55 Ekbom A, Helmick C, Zack M, Adami H O. Ulcerative colitis and colorectal cancer. A population based study.  N Engl J Med. 1990;  323 1228-1233
  CrossrefPubMedGoogle Scholar
• 56 Soetikno R M, Lin O S, Heidenreich P A, Young H S, Blackstone M O. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis.  Gastrointest Endosc. 2002;  56 48-54
  CrossrefPubMedGoogle Scholar
• 57 Bleday R, Lee E, Jessurun J, Heine J, Wong W D. Increased risk of early colorectal neoplasms after hepatic transplant in patients with inflammatory bowel disease.  Dis Colon Rectum. 1993;  36 908-912
  CrossrefPubMedGoogle Scholar
• 58 Higashi H, Yanaga K, Marsh J W et al.. Development of colon cancer after liver transplantation for primary sclerosing cholangitis associated with ulcerative colitis.  Hepatology. 1990;  11 477-480
  PubMedGoogle Scholar
• 59 Vera A, Gunson B K, Ussatoff V et al.. Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis.  Transplantation. 2003;  75 1983-1988
  CrossrefPubMedGoogle Scholar
• 60 Dvorchik I, Subotin M, Demetris A J et al.. Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis.  Hepatology. 2002;  35 380-384
  CrossrefPubMedGoogle Scholar
• 61 van de Vrie W, de Man R A, van Buuren H R et al.. Inflammatory bowel disease and liver transplantation for primary sclerosing cholangitis.  Eur J Gastroenterol Hepatol. 2003;  15 657-663
  PubMedGoogle Scholar
• 62 Eaden J. Review article: colorectal carcinoma and inflammatory bowel disease.  Aliment Pharmacol Ther. 2004;  20 24-30
  PubMedGoogle Scholar
• 63 Rutter M D, Saunders B P, Wilkinson K H et al.. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk.  Gut. 2004;  53 1813-1816
  CrossrefPubMedGoogle Scholar
• 64 Thomas R C, Selinger C, Rutter M D. Adherence to BSG adenoma surveillance guidelines will reduce colonoscopic workload.  Gut. 2005;  54 173 (Lett)
  PubMedGoogle Scholar
• 65 Nagggengast F, Grubben M, van Munster I. Role of bile acids in colorectal carcinogenesis.  Eur J Cancer. 1995;  31 1067-1070
  CrossrefPubMedGoogle Scholar
• 66 Marchesa P, Lashner B A, Lavery I C et al.. The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis.  Am J Gastroenterol. 1997;  92 1285-1288
  PubMedGoogle Scholar
• 67 Shetty K, Rybicki L, Brzezinski A, Carey W D, Lashner B A. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis.  Am J Gastroenterol. 1999;  94 1643-1649
  CrossrefPubMedGoogle Scholar
• 68 Lindberg B U, Broome U, Persson B. Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study.  Dis Colon Rectum. 2001;  44 77-85
  CrossrefPubMedGoogle Scholar
• 69 Pardi D S, Loftus E V, Kremers W K, Keach J, Lindor K D. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis.  Gastroenterology. 2003;  124 889-893
  CrossrefPubMedGoogle Scholar
• 70 Tung B Y, Emond M J, Haggitt R C et al.. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.  Ann Intern Med. 2001;  134 89-95
  CrossrefPubMedGoogle Scholar
• 71 Rutter M D, Saunders B P, Wilkinson K H, Kamm M A, Williams C B, Forbes A. Most dysplasia in ulcerative colitis is visible at colonoscopy.  Gastrointest Endosc. 2004;  60 334-339
  CrossrefPubMedGoogle Scholar
• 72 Eaden J. Review article: the data supporting a role for aminosalicylates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease.  Aliment Pharmacol Ther. 2003;  2 15-21
  PubMedGoogle Scholar
• 73 Bernstein C N, Eaden J, Steinhart A H, Munkholm P, Gordon P H. Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acid.  Inflamm Bowel Dis. 2002;  8 356-361
  PubMedGoogle Scholar
• 74 Ståhlberg D, Veress B, Tribukait B, Broomé U. Atrophy and neoplastic transformation of the ileal pouch mucosa in patients with ulcerative colitis and primary sclerosing cholangitis: a case control study.  Dis Colon Rectum. 2003;  46 770-778
  CrossrefPubMedGoogle Scholar
• 75 Hay J E, Wiesner R H, Shorter R G, La Russo N F, Baldus W P. Primary sclerosing cholangitis and celiac disease. A novel association.  Ann Intern Med. 1988;  109 713-717
  PubMedGoogle Scholar
• 76 Lindström E, Bodemar G, Ryden B O, Ihse I. Pancreatic ductal morphology and exocrine function in primary sclerosing cholangitis.  Acta Chir Scand. 1990;  156 451-456
  PubMedGoogle Scholar
• 77 Heikius B, Niemela S, Lehtola J, Karttunen T, Lahde S. Hepatobiliary and coexisting pancreatic duct abnormalities in patients with inflammatory bowel disease.  Scand J Gastroenterol. 1997;  32 153-161
  PubMedGoogle Scholar
• 78 Cangemi J R, Wiesner R W, Beaver S J, LaRusso N. Effect of proctocolectomy for chronic uclerative colitis on the natural history of primary sclerosing cholangitis.  Gastroenterology. 1989;  96 790-794
  PubMedGoogle Scholar
• 79 Martin F M, Rossi R L, Nugent F W et al.. Surgical aspects of sclerosing cholangitis. Results in 178 patients.  Ann Surg. 1990;  212 551-556
  PubMedGoogle Scholar
• 80 Fucini C, Wolff B G, Dozois R R. Bleeding from peristomal varices: perspectives on prevention and treatment.  Dis Colon Rectum. 1991;  34 1073-1078
  CrossrefPubMedGoogle Scholar
• 81 Wiesner R H, La Russo N F, Dozois R R, Beaver S J. Peristomal varices after proctocolectomy in patients with primary sclerosing cholangitis.  Gastroenterology. 1986;  90 316-322
  CrossrefPubMedGoogle Scholar
• 82 Peck J J, Boyden A M. Exigent ileostomy hemorrhage. A complication of proctocolectomy in patients with chronic ulcerative colitis and primary sclerosing cholangitis.  Am J Surg. 1985;  150 153-158
  CrossrefPubMedGoogle Scholar
• 83 Kartheuser A H, Dozois R R, La Russo N F et al.. Comparison of surgical treatment of ulcerative colitis associated with primary sclerosing cholangitis: ileal pouch-anal anastomosis versus Brooke ileostomy.  Mayo Clin Proc. 1996;  71 748-756
  PubMedGoogle Scholar
• 84 Vera A, Moledina S, Gunson B. Risk factors for recurrence of primary sclerosing cholangitis of liver allograft.  Lancet. 2002;  360(9349) 1943-1944
  CrossrefPubMedGoogle Scholar
• 85 Mac Lean A R, Lilly L, Cohen Z, O'Connor B, McLeod R S. Outcome of patients undergoing liver transplantation for primary sclerosing cholangitis.  Dis Colon Rectum. 2003;  46 1124-1128
  CrossrefPubMedGoogle Scholar
• 86 Ginsburg P M, Thuluvath P J. Diarrgea in liver transplant recipients: etiology and management.  Liver Transpl. 2005;  11 881-890
  CrossrefPubMedGoogle Scholar
• 87 Stephens J, Goldstein R, Crippin J et al.. Effects of orthotopic liver transplantation and immunosuppression on inflammatory bowel disease in primary sclerosing cholangitis patients.  Transplant Proc. 1993;  25 1122-1123
  PubMedGoogle Scholar
• 88 Befeler A S, Lissoos T W, Schiano T D et al.. Clinical course and management of inflammatory bowel disease after liver transplantation.  Transplantation. 1998;  65 393-396
  PubMedGoogle Scholar
• 89 Gavaler J S, Delemos B, Belle S H et al.. Ulcerative colitis disease activity as subjectively assessed by patient-completed questionnaires following orthotopic liver transplantation for sclerosing cholangitis.  Dig Dis Sci. 1991;  36 321-328
  CrossrefPubMedGoogle Scholar
• 90 Papatheodoridis G V, Hamilton M, Mistry P K, Davidson B, Rolles K, Burroughs A K. Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis.  Gut. 1998;  43 639-644
  PubMedGoogle Scholar
• 91 Knechtle S J, D’Alessandro A M, Harms B A et al.. Relationships between sclerosing cholangitis, inflammatory bowel disease, and cancer in patients undergoing liver transplantation.  Surgery. 1995;  118 615-619
  PubMedGoogle Scholar
• 92 Miki C, Harrison J D, Gunson B K et al.. Inflammatory bowel disease in primary sclerosing cholangitis: an analysis of patients undergoing liver transplantation.  Br J Surg. 1995;  82 1114-1117
  PubMedGoogle Scholar
• 93 Shaked A, Colonna J O, Goldstein L, Busuttil R W. The interrelation between sclerosing cholangitis and ulcerative colitis in patients undergoing liver transplantation.  Ann Surg. 1992;  215 598-603
  PubMedGoogle Scholar
• 94 Haagsma E B, Van Den Berg A P, Kleibeuker J H, Slooff M J, Dijkstra G. Inflammatory bowel disease after liver transplantation: the effect of different immunosuppressive regimens.  Aliment Pharmacol Ther. 2003;  18 33-44
  CrossrefPubMedGoogle Scholar
• 95 Cottone M, Pietrosi G, Martorana G et al.. Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn’s colitis.  Am J Gastroenterol. 2001;  96 773-775
  CrossrefPubMedGoogle Scholar
• 96 van de Vrie W, de Man R, van Buuren H et al.. Inflammatory bowel disease and liver transplantation for primary sclerosing cholangitis.  Eur J Gastroenterol Hepatol. 2003;  15 657-663
  PubMedGoogle Scholar
• 97 Saldeen K, Friman S, Olausson M, Olsson R. Follow-up after liver transplantation for primary sclerosing cholangitis: effects on survival, quality of life, and colitis.  Scand J Gastroenterol. 1999;  34 535-540
  CrossrefPubMedGoogle Scholar

Ulrika BrooméM.D. Ph.D. 

Department of Gastroenterology and Hepatology, Karolinska University Hospital, Huddinge

K63, 141 86 Stockholm, Sweden

Email: ulrika.broome@medhs.ki.se